Jakob Dupont, MD, on ATA188’s Potential in All Forms of Multiple Sclerosis

Video

The global head of research and development at Atara Biotherapeutics discussed ATA188 ahead of anticipated data readouts this month.

“We feel very strongly about trying to make a difference for these progressive MS patients, because it is such a high unmet need, and there are so few treatment options for these patients. We really hope that this is something that's quite impactful for these patients.”

Atara Biotherapeutics’ cell therapy ATA188 is in development for the potential treatment of multiple sclerosis (MS). Interim data analysis from the phase 2 EMBOLD study (NCT03283826) is expected in June 2022.1

The fast-tracked therapy targets Epstein-Barr virus (EBV)-infected cells for the potential treatment of MS and previously demonstrated positive data in its phase 1 study and open-label extension. This mechanism of action was validated after a publication in Science elucidated the relationship between MS and EBV, with a high prevalence of EBV infections associated with MS.2

CGTLive spoke with Jakob Dupont, MD, global head of research and development, Atara Biotherapeutics, to learn more about the progress of the EMBOLD study. He also discussed ATA188’s potential in meeting the high unmet needs of patients with progressive MS and also in other forms of MS.

REFERENCES
1. Atara Biotherapeutics announces first quarter 2022 financial results and operational progress. News release. Atara Biotherapeutics. May 5, 2022. https://investors.atarabio.com/news-events/press-releases/detail/276/atara-biotherapeutics-announces-first-quarter-2022
2. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022; 375(6578): 296-301. doi:10.1126/science.abj8222
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.